What’s really going on? –

JUNE 29, 2020 – The FDA has been pushing drugmakers to develop alternatives to opioid-based painkillers as the United States grapples with opioid addiction, with prescription opioids involved in 32% of all opioid overdose deaths in 2018, according to the Centers for Disease Control and Prevention. 

One of Heron’s biggest competitors for the non-opioid post-surgery painkiller is Pacira Biosciences Inc, whose long-acting Exparel is priced at $180.35 for a 10ml dose and $334.18 for the 20ml dose. 

The FDA had previously declined Heron’s application, citing issues relating to manufacturing at a contract drugmaker’s site, among other things.

more@Reuters

SIGN UP TODAY!

Subscribe Today! Your best source of current news, information and opinion about the issues that matter to you most. Serving the treatment industry, recovery community and health and wellness professionals.